Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu – szpital kliniczny Uniwersytetu Medycznego w Poznaniu. Główną siedzibą szpitala jest zabytkowy kompleks budynków dawnego Zakładu Diakonisek przy ul. Przybyszewskiego 49.

During the past decade, Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 8 clinical trials were completed, i.e. on average, 25.8% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 8 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Janssen Research & Development, LLC" with 6 trials sponsored, "Pfizer" with 4 trials sponsored, "Amgen" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu" #1 collaborator was "Biocompatibles UK Ltd" with 1 trials as a collaborator, "Merck Hellas sa., Greece, an affiliate of Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Ovid Therapeutics Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu" are "Multiple Myeloma" (5 trials), "Multiple Sclerosis" (4 trials), "Chemotherapy-induced Thrombocytopenia" (2 trials), "Epilepsy" (2 trials) and "Melanoma" (2 trials). Many other conditions were trialed in "Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu" in a lesser frequency.

Most popular intervention types in "Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu" are "Drug" (28 trials), "Biological" (2 trials), "Other" (2 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Atezolizumab" (4 trials), "Dexamethasone" (4 trials), "Bortezomib" (3 trials) and "Cobimetinib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu" are 35 trials for "All" genders.

Currently, there are NaN active trials in "Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu". undefined are not yet recruiting, 12 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 9 completed trials in Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".